FindTrial
Sign In

Effect of Sofosbuvir-daclatasuvir on Angiogenesis

Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03646396
Enrollment
40
Registered
2018-08-24
Start date
2018-08-01
Completion date
2025-12-31
Last updated
2018-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCV Coinfection

Brief summary

The study aimed at study of the Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection

Detailed description

The study primary aim was at evaluation of the Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection

Interventions

DRUGSofosbuvir-daclatasvir

Sofosbuvir-daclatasvir for 3 months

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Drug sof-Dakla

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Chronic HCV patients

Exclusion criteria

* HCC. * HIV or HBV. * Malignancy. * Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with change in VEGF, TGFB16 monthsNumber of patients with change in VEGF, TGFB1

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, MD
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026